Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $2,482,409.56 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 91,198 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.22, for a total value of $2,482,409.56. Following the sale, the insider directly owned 765,188 shares of the company’s stock, valued at approximately $20,828,417.36. This represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Enliven Therapeutics Trading Up 1.2%

Shares of ELVN opened at $26.05 on Thursday. The business’s 50-day moving average price is $19.46 and its 200 day moving average price is $20.05. The stock has a market capitalization of $1.55 billion, a P/E ratio of -14.16 and a beta of 0.41. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELVN has been the topic of several recent analyst reports. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $41.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after purchasing an additional 1,693 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Enliven Therapeutics during the 1st quarter worth $578,000. Rhumbline Advisers boosted its holdings in shares of Enliven Therapeutics by 4.9% during the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company’s stock worth $1,033,000 after buying an additional 2,466 shares during the period. Finally, KLP Kapitalforvaltning AS grew its stake in Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.